丙型肝炎抗病毒治疗：口服药物改变了什么?

doi:10.3969/j.issn.1672-5069.2016.04.001

Abstract

Luo Bifen, Wei Lai. Is hepatitis C eradicated possible[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 385-389.

[1] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南（2015更新版）. 中华肝脏病杂志,2015,23（12）:906-923.
[2] Kowdley KV,Gordon SC,Reddy KR,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med,2014,370（20）:1879-1888.
[3] Afdhal N,Zeuzem S,Kwo P,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med,2014,370（20）:1889-1898.
[4] Feld JJ,Kowdley KV,Coakley E,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med,2014,370（17）:1594-1603.
[5] Zeuzem S,Jacobson IM,Baykal T,et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med,2014,370（17）:1604-1614.
[6] Afdhal N,Reddy KR,Nelson DR,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med,2014,370（16）:1483-1493.
[7] Poordad F,Hezode C,Trinh R,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med, 2014,370（21）:1973-1982.
[8] Brown RS Jr, O'Leary JG, Reddy KR, et al. Hepatitis C therapeutic registry research network study group. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl, 2016,22（1）:24-33.
[9] Pillai AA,Wedd J,Norvell JP,et al. Simeprevir and sofosbuvir （SMV-SOF） for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: A real world （Transplant） hepatology practice experience. Am J Gastroenterol,2016,111（2）:250-260.
[10] Younossi ZM,Bacon BR,Dieterich DT,et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat,2016,23（6）:447-454.
[11] Sulkowski MS,Vargas HE,Di Bisceglie AM,et al. HCV-TARGET Study Group.Effectiveness of simeprevir plus sofosbuvir,with or without ribavirin,in real-world patients with HCV genotype 1 infection. Gastroenterology,2016,150（2）:419-429.
[12] Backus LI,Belperio PS,Shahoumian TA,et al. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology,2016 Apr 26. doi:10.1002/hep.28625[ahead of print].
[13] Zuckerman E,Ashkenasi E,Kovalev Y,et al. Te real-world Israeli experience of treating chronic hepatitis C,genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombita
svir,dasabuvir with or without ribavirin:a large multi-center cohort. J Hepatol,2016,64（supplement 2）:s137.
[14] Cheung MCM,Foster GR,Irving WL,et al. Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/daclatasvir with or without ribavirin 6 and 12 month outcomes compared to untreated patients. J Hepatol,2016,64（supplement 2）:s185.
[15] http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-20
16/en/16]European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol, 2015,63（1）:199-236.
[17] AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing,managing,and treating adults infected with hepatitis C virus. Hepatology, 2015,62（3）:932-954.
[18] Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens. J Hepatol, 2016 Apr 13. pii: S0168-8278（16）30108-8. doi:10.1016/j.jhep.2016.04.006.
[19] Colombo M,Aghemo A,Liu L,et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. J Hepatol, 2016,64（supplement 2）:s183.
[20] Wang C,Ji D,Chen J,et al. Hepatitis B reactivation in CHC Chinese treated with pan-oral DAAs-a prospective study. Hepatol Int,2016,10 （Suppl 1）:S51.
[21] Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 2016 Apr 11. pii: S0016-5085（16） 30055-5. doi:10.1053/j.gastro.2016.04.003.
[22] Susser S,Dietz J,Vermehren J,et al. European RAVs database: frequency and characteristics of RAVs in treatment naive and DAA-experienced patients. J Hepatol,2016,64（supplement 2）:s139.
[23] Gane EJ,Shiffman ML,Etzkorn K,et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens:results of the GS-US-342-1553 study. J Hepatol,2016,64（supplement 2）:s147.
[24] Poordad F,Gordon SC,Asatryan A,et al. High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the magellan-I study. J Hepatol,2016,64（supplement 2）:s160.
[25] Shiratori Y,Imazeki F,Moriyama M,et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med,2000,132（7）:517-524.
[26] Yoshida H,Arakawa Y,Sata M,et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology,2002,123（2）:483-491.
[27] Shiratori Y,Shiina S,Teratani T,et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med, 2003,138（4）:299-306.

Is hepatitis C eradicated possible

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[6]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[7]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[8]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[9]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[10]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[11]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[12]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[13]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[14]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.
[15]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.